As of 2025-02-19, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -0.48. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 57.26 mil USD. INO's TTM EBITDA according to its financial statements is -119.63 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
Range | Selected | |
Trailing P/E multiples | 13.6x - 15.8x | 15.3x |
Forward P/E multiples | 16.8x - 23.3x | 21.1x |
Fair Price | (55.28) - (51.96) | (59.80) |
Upside | -2624.3% - -2472.8% | -2830.4% |
Date | EV/EBITDA |
2025-02-18 | -0.48 |
2025-02-14 | -0.47 |
2025-02-13 | -0.46 |
2025-02-12 | -0.46 |
2025-02-11 | -0.39 |
2025-02-10 | -0.40 |
2025-02-07 | -0.41 |
2025-02-06 | -0.42 |
2025-02-05 | -0.43 |
2025-02-04 | -0.42 |
2025-02-03 | -0.42 |
2025-01-31 | -0.45 |
2025-01-30 | -0.45 |
2025-01-29 | -0.43 |
2025-01-28 | -0.48 |
2025-01-27 | -0.50 |
2025-01-24 | -0.48 |
2025-01-23 | -0.51 |
2025-01-22 | -0.50 |
2025-01-21 | -0.48 |
2025-01-17 | -0.45 |
2025-01-16 | -0.39 |
2025-01-15 | -0.38 |
2025-01-14 | -0.38 |
2025-01-13 | -0.39 |
2025-01-10 | -0.42 |
2025-01-08 | -0.45 |
2025-01-07 | -0.51 |
2025-01-06 | -0.40 |
2025-01-03 | -0.41 |
2025-01-02 | -0.37 |
2024-12-31 | -0.37 |
2024-12-30 | -0.36 |
2024-12-27 | -0.38 |
2024-12-26 | -0.38 |
2024-12-24 | -0.37 |
2024-12-23 | -0.36 |
2024-12-20 | -0.37 |
2024-12-19 | -0.37 |
2024-12-18 | -0.36 |
2024-12-17 | -0.41 |
2024-12-16 | -0.47 |
2024-12-13 | -0.52 |
2024-12-12 | -0.95 |
2024-12-11 | -1.03 |
2024-12-10 | -1.03 |
2024-12-09 | -1.07 |
2024-12-06 | -1.08 |
2024-12-05 | -1.03 |
2024-12-04 | -1.06 |